204 related articles for article (PubMed ID: 18546273)
1. A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma.
Yao M; Huang Y; Shioi K; Hattori K; Murakami T; Sano F; Baba M; Kondo K; Nakaigawa N; Kishida T; Nagashima Y; Yamada-Okabe H; Kubota Y
Int J Cancer; 2008 Sep; 123(5):1126-32. PubMed ID: 18546273
[TBL] [Abstract][Full Text] [Related]
2. Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma.
Chen D; Gassenmaier M; Maruschke M; Riesenberg R; Pohla H; Stief CG; Zimmermann W; Buchner A
J Urol; 2014 Feb; 191(2):479-86. PubMed ID: 24012533
[TBL] [Abstract][Full Text] [Related]
3. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases.
Wuttig D; Zastrow S; Füssel S; Toma MI; Meinhardt M; Kalman K; Junker K; Sanjmyatav J; Boll K; Hackermüller J; Rolle A; Grimm MO; Wirth MP
Int J Cancer; 2012 Sep; 131(5):E693-704. PubMed ID: 22213152
[TBL] [Abstract][Full Text] [Related]
4. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
[TBL] [Abstract][Full Text] [Related]
5. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
6. Expression of aquaporin 1 in primary renal tumors: a prognostic indicator for clear-cell renal cell carcinoma.
Huang Y; Murakami T; Sano F; Kondo K; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Eur Urol; 2009 Oct; 56(4):690-8. PubMed ID: 18930582
[TBL] [Abstract][Full Text] [Related]
7. Microarray gene expression profiling and analysis in renal cell carcinoma.
Liou LS; Shi T; Duan ZH; Sadhukhan P; Der SD; Novick AA; Hissong J; Skacel M; Almasan A; DiDonato JA
BMC Urol; 2004 Jun; 4():9. PubMed ID: 15212686
[TBL] [Abstract][Full Text] [Related]
8. Differential expression in clear cell renal cell carcinoma identified by gene expression profiling.
Lane BR; Li J; Zhou M; Babineau D; Faber P; Novick AC; Williams BR
J Urol; 2009 Feb; 181(2):849-60. PubMed ID: 19095258
[TBL] [Abstract][Full Text] [Related]
9. Gene signatures of progression and metastasis in renal cell cancer.
Jones J; Otu H; Spentzos D; Kolia S; Inan M; Beecken WD; Fellbaum C; Gu X; Joseph M; Pantuck AJ; Jonas D; Libermann TA
Clin Cancer Res; 2005 Aug; 11(16):5730-9. PubMed ID: 16115910
[TBL] [Abstract][Full Text] [Related]
10. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma.
Yao M; Tabuchi H; Nagashima Y; Baba M; Nakaigawa N; Ishiguro H; Hamada K; Inayama Y; Kishida T; Hattori K; Yamada-Okabe H; Kubota Y
J Pathol; 2005 Feb; 205(3):377-87. PubMed ID: 15682440
[TBL] [Abstract][Full Text] [Related]
11. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy.
Sejima T; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
Urol Int; 2012; 88(3):263-70. PubMed ID: 22398398
[TBL] [Abstract][Full Text] [Related]
12. CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.
Chong TW; Goh FY; Sim MY; Huang HH; Thike AA; Lim WK; Teh BT; Tan PH
J Clin Pathol; 2015 Mar; 68(3):200-5. PubMed ID: 25477528
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.
Heinzelmann J; Unrein A; Wickmann U; Baumgart S; Stapf M; Szendroi A; Grimm MO; Gajda MR; Wunderlich H; Junker K
Ann Surg Oncol; 2014 Mar; 21(3):1046-54. PubMed ID: 24242678
[TBL] [Abstract][Full Text] [Related]
14. Expression of adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal carcinoma.
Yao M; Huang Y; Shioi K; Hattori K; Murakami T; Nakaigawa N; Kishida T; Nagashima Y; Kubota Y
Clin Cancer Res; 2007 Jan; 13(1):152-60. PubMed ID: 17200350
[TBL] [Abstract][Full Text] [Related]
15. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
[TBL] [Abstract][Full Text] [Related]
16. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
17. High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma.
Liu Y; Yang L; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Sci Rep; 2015 Nov; 5():16954. PubMed ID: 26599282
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
[TBL] [Abstract][Full Text] [Related]
19. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
[TBL] [Abstract][Full Text] [Related]
20. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
